English

Choose language

Back

  • Deutsch

  • English

  • Español

  • Français

  • Polski

  • Русский

  • Українська


English

Shares Roche Holding

12.32%
Growth potential
257.45
Price per 1 share
EUR
2.74%
Dividend income
Roche Holding sold in lots of 10 pc.
Enter the number of securities
Order price:
Brokerage commission:
Transfer commission:
Doing now what patients need next
Why invest in Roche Holding?
  • One of the leading companies in pharmaceuticals and diagnostics
  • Develops drugs in oncology, immunology, ophtalmology, infection disease, and neurology domains
  • Over CHF 235B market cap as of now
  • CHF 9.5M net profit in 2017


1d
1w
1mo
6mths
All the time
Recommendations of the largest investment banks
UBS AG
Buy
360 €
02.09.2020
Morgan Stanley
Buy
343 €
10.08.2020
Barclays Capital
Buy
366 €
10.08.2020
Bernstein Research
Buy
352 €
10.08.2020
Financial indicators
Capitalization
249.72B €
P / E
19.68
Profit
N/A €
Net profit
46.37B €
The general recommendation of investment banks

Buy

Based on the analytics from 28 of the world's largest investment banks over the past 3 months

Forecasted prices

Target price

295.3 €

(13.31% Growth potential)

Based on the data from 28 of the leading investment banks

Roche Holding Ltd. – a pharmaceutical holding headed by F. Hoffmann-La Roche company, a Swiss manufacturer of medical drugs and diagnostic equipment. Besides the Swiss, it includes Japanese and North American companies. Founded in 1896, the parent corporation quickly claimed leading positions in the market, and in 1919 became a joint stock company. In the 1930s, Roche extended its product line with vitamins, in the 1960s it started producing a popular valium. Nowadays, Roche has transferred fragrance and vitamin production into separate companies and has focused on manufacturing diagnostic equipment and medicine for people with AIDS, oncology, and organ transplantation. Among the latest achievements is a medication against the Tamiflu. According to statistics, the largest profit in the field of pharmacology the company receives from antitumor drugs and in the field of medical equipment – from glucometers and equipment for immunodiagnostics cycle. Roche invests significant funds in research performed by Genentech subsidiary that successfully works on the diagnosing and treating genetic diseases, in particular, the problem of dwarfism.

In 2017, the annual turnover of Roche holding amounted to about 53 billion Swiss francs, with the net profit of 9.5 billion. Compared to the year 2015 that was not the most successful for the company, the indicators increased by 10% and 5% respectively. The Roche stocks are quite a reliable investment, from which one cannot expect either a huge profit or serious failures.

Receive ideas for profitable investments - faster than the market

We will be sending you a letter once a week with the most relevant information

Congratulations!

Now you will always be aware of which stocks are more profitable to invest in